Colorectal cancer peritoneal metastases: Biology, treatment and next steps

Eur J Surg Oncol. 2020 Apr;46(4 Pt A):675-683. doi: 10.1016/j.ejso.2019.10.035. Epub 2019 Oct 31.

Abstract

The presence of peritoneal metastases in patients with advanced colorectal cancer is associated with poor prognosis but the mechanisms for this are unclear. This review summarises the current knowledge of the pathophysiology, clinical features, prevalence, prognosis, and molecular biology of peritoneal metastases and the risk factors for the development of peritoneal metastases following resection of a primary colorectal tumour. Furthermore, the evidence for treatment strategies are described including cytoreductive surgery, hyperthermic intraperitoneal chemotherapy, early post-operative intraperitoneal chemotherapy, sequential post-operative intraperitoneal chemotherapy and emerging novel strategies. Active areas of research should include the identification of individuals at high risk of peritoneal metastases after curative resection of primary tumour, development of a surveillance program for high-risk patients, optimisation of systematic therapies and further investigation of the use of intraperitoneal chemotherapy.

Keywords: Biology; Colorectal cancer; Intraperitoneal chemotherapy; Peritoneal metastases; Treatment.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carcinoma / genetics
  • Carcinoma / secondary
  • Carcinoma / therapy*
  • Chemotherapy, Adjuvant
  • Colorectal Neoplasms / genetics
  • Colorectal Neoplasms / pathology*
  • Cytoreduction Surgical Procedures*
  • Humans
  • Hyperthermia, Induced
  • Immunotherapy, Adoptive
  • Infusions, Parenteral
  • Peritoneal Neoplasms / genetics
  • Peritoneal Neoplasms / secondary
  • Peritoneal Neoplasms / therapy*
  • Prognosis
  • Proto-Oncogene Proteins B-raf / genetics
  • Proto-Oncogene Proteins p21(ras) / genetics
  • Risk Factors

Substances

  • Antineoplastic Agents
  • KRAS protein, human
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf
  • Proto-Oncogene Proteins p21(ras)